Abbott Laboratories and Myriad Genetics are joining forces to allow the drugmaker to draw on Myriad's genetics and other drug-discovery technologies to produce novel products. Under the pact, Myriad will work to identify the genetic bases of diseases so Abbott can identify targets for drugs it might want to develop.

Related Summaries